**Author details**

Yuko Kanbayashi1,2\* and Toyoshi Hosokawa2,3,4

\*Address all correspondence to: ykokanba@koto.kpu-m.ac.jp

1 Department of Hospital Pharmacy, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

2 Pain Treatment & Palliative Care Unit, University Hospital, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

3 Department of Anaesthesiology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

[14] Dworkin RH, Nagasako EM, Johnson RW, Griffin DR. Acute pain in herpes zoster: the

Predictive Factors for Postherpetic Neuralgia and Recent Pharmacotherapies

http://dx.doi.org/10.5772/55278

161

[15] Kurokawa I, Kumano K, Murakawa K. Hyogo Prefectural PHN Study Group. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med

[16] Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, Breuer J. A study of shingles and the development of postherpetic neuralgia in East

[17] Nithyanandam S, Dabir S, Stephen J, Joseph M. Eruption severity and characteristics in herpes zoster ophthalmicus: correlation with visual outcome, ocular complications,

[18] Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, Verheij TJ, Moons KG. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132: S52-S59. [19] Parruti G, Tontodonati M, Rebuzzi C, Polilli E, Sozio F, Consorte A, Agostinone A, Di Masi F, Congedo G, D'Antonio D, Granchelli C, D'Amario C, Carunchio C, Pippa L, Manzoli L, Volpi A; VZV Pain Study Group. Predictors of pain intensity and persistence in a prospective Italian cohort of patients with herpes zoster: relevance of smoking,

[20] Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and psychosocial

[21] McKendrick MW, Ogan P, Care CC. A 9 year follow up of post herpetic neuralgia and predisposing factors in elderly patients following herpes zoster. J Infect 2009; 59:

[22] Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. Predictors of postherpetic neuralgia among patients with herpes zoster: a

[23] Mick G, Gallais JL, Simon F, Pinchinat S, Bloch K, Beillat M, Serradell L, Derrough T. Burden of herpes zoster and postherpetic neuralgia: Incidence, proportion, and associated costs in the French population aged 50 or over. Rev Epidemiol Sante

[24] Kanbayashi Y, Onishi K, Fukazawa K, Okamoto K, Ueno H, Takagi T, Hosokawa T. Predictive Factors for Postherpetic Neuralgia Using Ordered Logistic Regression

[25] Johnson RW. Zoster-associated pain: what is known, who is at risk and how can it be

[26] Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008; 9:

correlates of post-herpetic neuralgia. J Med Virol 2008; 80: 1646-1652.

famciclovir database project. Pain 2001; 94: 113-119.

and postherpetic neuralgia. Int J Dermatol 2009; 48: 484-487.

trauma and antiviral therapy. BMC Med 2010; 8: 58.

prospective study. J Pain 2010; 11: 1211-1221.

Publique 2010; 58: 393-401.

Analysis. Clin J Pain 2011, in press.

managed? Herpes 2007; 14: 30-34.

London. J Med Virol 2003; 70: S24-S30.

Res 2002; 30: 56-65.

416-420.

S19-30.

4 Pain Management & Palliative Care Medicine, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan

#### **References**


[14] Dworkin RH, Nagasako EM, Johnson RW, Griffin DR. Acute pain in herpes zoster: the famciclovir database project. Pain 2001; 94: 113-119.

3 Department of Anaesthesiology, Kyoto Prefectural University of Medicine, Graduate

160 Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder

4 Pain Management & Palliative Care Medicine, Kyoto Prefectural University of Medicine,

[1] Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia

[2] Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009; 2. CD006866.

[3] Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia

[4] Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:

[5] Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic

[6] Johnson RW. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010; 9:

[7] McElhaney JE. Herpes zoster: a common disease that can have a devastating impact on

[8] Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. J Int J Clin Pract 2009;

[9] Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological

[10] Whitley RJ, Volpi A, McKendrick M, Wijck A, Oaklander AL. Management of herpes zoster and post-herpetic neuralgia now and in the future. J Clin Virol 2010; 48:S20-S28.

[11] Attal N, Cruccu G, Baron R, Haanpää M, Hansson P, Jensen TS, Nurmikko T; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treat‐

[12] Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010; 149: 338-344.

[13] Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia

ment of neuropathic pain: 2010 revision. Eur J Neurol 2010; 17: 1113-e88.

and painful diabetic neuropathy. Clin J Pain 2002; 18: 350-354.

patients' quality of life. Expert Rev Vaccines 2010; 9: 27-30.

mechanisms, and treatment. Lancet Neurol 2010; 9: 807-819.

in patients with herpes zoster. Neurology 2004; 62: 1545-1551.

neuralgia. Mayo Clin Proc. 2009; 84: 274-280.

School of Medical Science, Kyoto, Japan

**References**

241-251.

21-26.

63: 1386-1391.

Graduate School of Medical Science, Kyoto, Japan

J Intern Med 2011; 269: 496-506.


[27] Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: e164.

[41] National Cancer Institute. National Cancer Institute of the National Institutes of Health (NIH). NCI Thesaurus. 2012 http://ncit.nci.nih.gov/ncitbrowser/pages/home.jsf

Predictive Factors for Postherpetic Neuralgia and Recent Pharmacotherapies

http://dx.doi.org/10.5772/55278

163

[42] Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev

[43] Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic

[44] Sindrup SH, Otto M, Finnerup NB, Jensen TS. Antidepressants in the treatment of

[45] Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J

[46] Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk

[47] Tata LJ, West J, Smith C, Farrington P, Card T, Smeeth L, Hubbard R. General popu‐ lation based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart 2005; 91: 465-471. [48] Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992; 326:

[49] Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166-1171.

[50] Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith I, Warsh J. Amitriptyline versus

[51] Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427-1432. [52] Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic

[53] Raskin J, Smith TR, Wong K, Pritchett YL, D'Souza DN, Iyengar S, Wernicke JF. Duloxetine versus routine care in the long-term management of diabetic peripheral

[54] Wernicke JF, Pritchett YL, D'Souza DN, Waninger A, Tran P, Iyengar S, Raskin J. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.

[55] Sang CN, Booher S, Gilron I, Parada S, Max MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response

pain treatment: an evidence based proposal. Pain 2005; 118: 289-305.

neuropathic pain. Basic Clin Pharmacol Toxicol 2005; 96: 399-409.

of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234-241.

placebo in postherpetic neuralgia. Neurology 1982; 32: 671-673.

pain. Cochrane Database Syst Rev 2009; 4: CD007115.

neuropathic pain. J Palliat Med 2006; 9: 29-40.

trials. Anesthesiology 2002; 96: 1053-1061.

Neurology 2006; 67: 1411-1420.

(accessed 12 August).

2007; 4: CD005454.

Med 2000; 108: 2-8.

1250-1256.


[41] National Cancer Institute. National Cancer Institute of the National Institutes of Health (NIH). NCI Thesaurus. 2012 http://ncit.nci.nih.gov/ncitbrowser/pages/home.jsf (accessed 12 August).

[27] Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: e164.

[28] Benzon HT, Chekka K, Darnule A, Chung B, Wille O, Malik K. Evidence-based case report: the prevention and management of postherpetic neuralgia with emphasis on

[29] Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad

[30] Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-

[31] Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H; Quality Standards Subcom‐ mittee of the American Academy of Neurology. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcom‐

mittee of the American Academy of Neurology. Neurology. 2004; 63: 959-965.

[32] The Committee for the Guidelines for the Pharmacologic Management of Neuropathic Pain of JSPC. Guidelines for the Pharmacologic Management of Neuropathic Pain.

[33] Moore RA, Wiffen PJ, Derry S, McQuay HJ. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011; 3: CD007938.

[34] Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic

[35] National Cancer Institute. National Cancer Institute of the National Institutes of Health (NIH). Cancer topics, In: Cancer Drug Information. 2012 http://www.cancer.gov/

[36] Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized,

[37] Cappuzzo KA. Treatment of postherpetic neuralgia: focus on pregabalin. Clin Interv

[38] Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in

[39] Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, Royall RM, Max MB. Opioids versus antidepressants in postherpetic neuralgia: a randomized,

[40] Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104: 323–331.

controlled trials across a range of doses. Diabetes Care 2008; 31: 1448-1454.

pain in adults. Cochrane Database Syst Rev 2009; 3: CD007076.

postherpetic neuralgia. Neurology 1998; 50: 1837-1841.

placebo-controlled trial. Neurology 2002; 59: 1015-1021.

interventional procedures. Reg Anesth Pain Med 2009; 34: 514-21.

162 Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder

based recommendations. Pain 2007; 132: 237-251.

Med 2011; 123: 134-142.

Tokyo: Shinko Trading; 2011.

drugdictionary (accessed 12 August).

Aging 2009; 4: 17-23.


[56] Wallace MS, Rowbotham MC, Katz NP, Dworkin RH, Dotson RM, Galer BS, Rauck RL, Backonja MM, Quessy SN, Meisner PD. A randomized, double-blind, placebocontrolled trial of a glycine antagonist in neuropathic pain. Neurology 2002; 59:

164 Peripheral Neuropathy - A New Insight into the Mechanism, Evaluation and Management of a Complex Disorder

[57] Kawashiri T, Egashira N, Watanabe H, Ikegami Y, Hirakawa S, Mihara Y, Yano T, Ikesue H, Oishi R. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model. Eur J Pain. 2011; 15:344-50.

[58] Kudo T, Kushikata T, Kudo M, Kudo T, Hirota K. Antinociceptive effects of neurotropin in a rat model of central neuropathic pain: DSP-4 induced noradrenergic lesion.

1694-1700.

Neurosci Lett. 2011; 503:20-2.
